4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), will be publishing its interim results for the six months ended 30 June 2012 on Thursday 6 September 2012.
Tony Baxter, Chief Executive Officer, and John Dootson, Chief Financial Officer, will present the results to analysts at 9.30am at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London,
WC2A 1PB.
Enquiries:
Cyprotex PLC Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com
Singer Capital Markets Limited (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com
FTI Consulting Tel: +44 (0) 20 7831 3113
Simon Conway
Mo Noonan
cyprotex@fticonsulting.com
www.fticonsulting.com
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com